Eyegate Pharmaceuticals Inc (EYEG) 6.1500 $EYEG
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
GlobeNewswire - Fri Jul 10, 7:30AM CDT
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) ("Valeant" through which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to its EyeGate(R) II Delivery System and EGP-437 combination product ("Product" in the field of uveitis, as well as a right of last negotiation to license the Product for other indications.
VRX: 232.32 (+8.93), VRX.TO: 294.65 (+11.22)
Cataract - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d86sd5/cataract) has announced the addition of the "Cataract - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - CalAsia Pharmaceuticals, Inc. - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Laila Pharmaceuticals Pvt. Ltd. - Omeros Corporation - R-Tech Ueno, Ltd. For more information visit http://www.researchandmarkets.com/research/d86sd5/cataract
OMER: 17.33 (+0.29)
Corneal Graft Rejection - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bm8b9w/corneal_graft) has announced the addition of the "Corneal Graft Rejection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Corneal Graft Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Graft Rejection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Circadian Technologies Limited - EyeGate Pharmaceuticals, Inc. - Oxford BioMedica plc For more information visit http://www.researchandmarkets.com/research/bm...neal_graft
Uveitis Pipeline Review, H1 2015
M2 - Thu Jun 11, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvvmhf/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aciont Inc. - Apitope International NV - BBB Therapeutics B.V. - Can-Fite BioPharma Ltd. - Clearside BioMedical, Inc. - Effimune SAS - Eleven Biotherapeutics Inc. - Endocyte, Inc. - Enzo Biochem, Inc. - EyeGate Pharmaceuticals, Inc. - ForSight VISION4, Inc. - HanAll Biopharma Co., Ltd. - Icon Bioscience, Inc. - IMMD Inc. - Johnson & Johnson - Neuroptis Biotech - Novartis AG - Ocata Therapeutics, Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. - Pfizer Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SynDevRx, Inc. - TxCell SA - Virogenomics, Inc. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/xvvmhf/uveitis
OCAT: 5.22 (+0.14), PFE: 34.36 (+0.50), CANF: 2.00 (+0.09), JNJ: 99.53 (+1.13), ECYT: 5.43 (+0.17), ENZ: 3.00 (+0.04), ABBV: 69.23 (+1.26), REGN: 526.01 (+16.98), XOMA: 4.72 (+0.23), NVS: 103.22 (+3.20)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
Global Anterior Uveitis Pipeline Review 2015 - 4 Companies & 5 Drug Profiles
M2 - Wed May 20, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnrxp7/anterior_uveitis) has announced the addition of the "Anterior Uveitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - EyeGate Pharmaceuticals, Inc. - Neuroptis Biotech - Virogenomics, Inc. - XOMA Corporation Drug Profiles - dexamethasone acetate - gevokizumab - NOP-3 - NS2 - Peptides to Modulate TCR for Uveitis For more information visit http://www.researchandmarkets.com/research/hn...or_uveitis
XOMA: 4.72 (+0.23)
EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
GlobeNewswire - Mon May 04, 8:03AM CDT
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced receipt of comments from the U.S. Food & Drug Administration ("FDA" in response to questions submitted by the Company ahead of a Type B meeting scheduled for May 5, 2015. The FDA provided guidance that if the planned Phase 3 trial of EGP-437 in anterior uveitis meets non-inferiority criteria, data from this trial along with data from a previously completed Phase 3 trial in anterior uveitis will be sufficient to support a New Drug Application ("NDA" filing. The FDA also communicated that the design of the planned Phase 3 is acceptable and that the nonclinical work completed to date is sufficient to support a NDA filing. Based on this positive feedback, the Company has elected to cancel the face-to-face portion of the meeting.
EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:40PM CDT
Eyegate Pharmaceuticals, Inc. (OTCBB:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced its financial results for the year ended December 31, 2014.
Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer
GlobeNewswire - Mon Mar 02, 7:35AM CST
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the appointment of Michael B. Raizman, MD as the Consulting Chief Medical Officer. Dr. Raizman began working with the Company as a consultant in the fourth quarter of 2014.
InsiderInsights.com Daily Round Up 2/23/15: MDLZ, GPRO, MDGN, CRR
InsiderInsights - at Seeking Alpha - Tue Feb 24, 6:07AM CST
GPRO: 52.51 (+0.47), LDRH: 41.19 (+1.15), MDLZ: 41.41 (+0.16), HCOM: 25.12 (+0.08), CRR: 35.74 (-0.45), MDGN: 6.47 (+0.37), DEI: 28.34 (+0.15), WETF: 21.90 (+0.40), BBY: 33.93 (+0.26), AON: 101.78 (+1.63), GOOG: 530.13 (+9.45), LEA: 104.21 (+0.88), AJX: 13.98 (+0.18), PLAY: 36.62 (+0.59), CTSH: 59.71 (+0.22), BLPH: 7.92 (-0.15), OMI: 33.76 (+0.58)
Eyegate Pharma closes IPO
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 11:42AM CST
Eyegate Pharma prices IPO
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:13AM CST
IPO Market Set For Another Surge In The Healthcare Sector
Renaissance Capital IPO Research - at Seeking Alpha - Mon Feb 02, 6:15PM CST
Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the two dividend-producing IPOs seek to price late in the week. The remaining eight...
AVGR: 12.90 (+0.18), IDGX: (), SLWD: (), ITEK: 5.11 (+0.25), REDX: (), INOV: 27.01 (+0.32), PUMP: (), CBYL: 7.26 (+0.31), NVET: 4.51 (-0.21), AAAP: ()
EyeGate Pharma back resets for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:29PM CST
Week Ahead: IPO Market Gains Momentum With 12 Deals Including Shake Shack And Health Care
Renaissance Capital IPO Research - Seeking Alpha - Tue Jan 27, 7:03AM CST
Twelve IPOs are set to raise $1 billion in the upcoming week, which would make it the busiest five-day stretch for IPOs since the week of July 28. Shake Shack's IPO offers investors a chance to own a fast-growing fast casual concept based in New...
AVGR: 12.90 (+0.18), SHAK: 50.50 (+0.07), ASND: 19.38 (-0.22), HIFR: 30.98 (unch), REDX: (), ONCE: 60.80 (+1.43), ENTL: 24.09 (-0.01), ZSAN: 8.26 (+0.49), FLKS: 17.02 (+0.52), LENS: 7.05 (+0.23), TCON: 10.80 (+0.13)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 312.13 (+8.03), OHRP: 2.27 (-0.07), REGN: 526.01 (+16.98), OMER: 17.33 (+0.29), NVS: 103.22 (+3.20)
Cataract Therapeutic Pipeline Market Review by Companies and Drugs H2 2014 Report at RnRMarketResearch.com
PRWeb - Fri Nov 21, 7:31AM CST
The report "Cataract - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/cataract-pip...eport.html .
Solar Power, Biotechs Among 11 IPOs Planned This Week
at Investor's Business Daily - Mon Sep 29, 6:24PM CDT
The IPO market is maintaining a brisk pace with 11 scheduled this week, including a solar power company, three tech firms and three biotech companies. Vivint Solar (VSLR), a competitor to the Elon Musk-backed SolarCity (SCTY), plans to raise $350...
ATTO: 13.80 (-0.08), VWR: 25.43 (-0.23), JMEI: 19.32 (+0.58), ZEN: 21.44 (+0.35), VSLR: 11.34 (+0.39), JPEP: 12.97 (+0.11), W: 37.35 (+1.03), FMSA: 6.73 (-0.27), SCTY: 53.00 (+1.02), DERM: 18.22 (+0.30), AAC: 42.41 (-1.20), CALA: 6.77 (unch), AAVL: 16.25 (+0.62), YDLE: 14.67 (+0.56), JD: 32.40 (-0.38), BABA: 80.30 (+1.26)
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
GlobeNewswire - Fri Jul 10, 7:30AM CDT
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) ("Valeant" through which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to its EyeGate(R) II Delivery System and EGP-437 combination product ("Product" in the field of uveitis, as well as a right of last negotiation to license the Product for other indications. VRX: 232.32 (+8.93), VRX.TO: 294.65 (+11.22)
Cataract - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d86sd5/cataract) has announced the addition of the "Cataract - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - CalAsia Pharmaceuticals, Inc. - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Laila Pharmaceuticals Pvt. Ltd. - Omeros Corporation - R-Tech Ueno, Ltd. For more information visit http://www.researchandmarkets.com/research/d86sd5/cataract
OMER: 17.33 (+0.29)
Corneal Graft Rejection - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bm8b9w/corneal_graft) has announced the addition of the "Corneal Graft Rejection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Corneal Graft Rejection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Graft Rejection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Circadian Technologies Limited - EyeGate Pharmaceuticals, Inc. - Oxford BioMedica plc For more information visit http://www.researchandmarkets.com/research/bm...neal_graft
Uveitis Pipeline Review, H1 2015
M2 - Thu Jun 11, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvvmhf/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aciont Inc. - Apitope International NV - BBB Therapeutics B.V. - Can-Fite BioPharma Ltd. - Clearside BioMedical, Inc. - Effimune SAS - Eleven Biotherapeutics Inc. - Endocyte, Inc. - Enzo Biochem, Inc. - EyeGate Pharmaceuticals, Inc. - ForSight VISION4, Inc. - HanAll Biopharma Co., Ltd. - Icon Bioscience, Inc. - IMMD Inc. - Johnson & Johnson - Neuroptis Biotech - Novartis AG - Ocata Therapeutics, Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. - Pfizer Inc. - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SynDevRx, Inc. - TxCell SA - Virogenomics, Inc. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/xvvmhf/uveitis
OCAT: 5.22 (+0.14), PFE: 34.36 (+0.50), CANF: 2.00 (+0.09), JNJ: 99.53 (+1.13), ECYT: 5.43 (+0.17), ENZ: 3.00 (+0.04), ABBV: 69.23 (+1.26), REGN: 526.01 (+16.98), XOMA: 4.72 (+0.23), NVS: 103.22 (+3.20)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
Global Anterior Uveitis Pipeline Review 2015 - 4 Companies & 5 Drug Profiles
M2 - Wed May 20, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnrxp7/anterior_uveitis) has announced the addition of the "Anterior Uveitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - EyeGate Pharmaceuticals, Inc. - Neuroptis Biotech - Virogenomics, Inc. - XOMA Corporation Drug Profiles - dexamethasone acetate - gevokizumab - NOP-3 - NS2 - Peptides to Modulate TCR for Uveitis For more information visit http://www.researchandmarkets.com/research/hn...or_uveitis
XOMA: 4.72 (+0.23)
EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
GlobeNewswire - Mon May 04, 8:03AM CDT
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced receipt of comments from the U.S. Food & Drug Administration ("FDA" in response to questions submitted by the Company ahead of a Type B meeting scheduled for May 5, 2015. The FDA provided guidance that if the planned Phase 3 trial of EGP-437 in anterior uveitis meets non-inferiority criteria, data from this trial along with data from a previously completed Phase 3 trial in anterior uveitis will be sufficient to support a New Drug Application ("NDA" filing. The FDA also communicated that the design of the planned Phase 3 is acceptable and that the nonclinical work completed to date is sufficient to support a NDA filing. Based on this positive feedback, the Company has elected to cancel the face-to-face portion of the meeting. EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:40PM CDT
Eyegate Pharmaceuticals, Inc. (OTCBB:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced its financial results for the year ended December 31, 2014. Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer
GlobeNewswire - Mon Mar 02, 7:35AM CST
Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the appointment of Michael B. Raizman, MD as the Consulting Chief Medical Officer. Dr. Raizman began working with the Company as a consultant in the fourth quarter of 2014. InsiderInsights.com Daily Round Up 2/23/15: MDLZ, GPRO, MDGN, CRR
InsiderInsights - at Seeking Alpha - Tue Feb 24, 6:07AM CST
GPRO: 52.51 (+0.47), LDRH: 41.19 (+1.15), MDLZ: 41.41 (+0.16), HCOM: 25.12 (+0.08), CRR: 35.74 (-0.45), MDGN: 6.47 (+0.37), DEI: 28.34 (+0.15), WETF: 21.90 (+0.40), BBY: 33.93 (+0.26), AON: 101.78 (+1.63), GOOG: 530.13 (+9.45), LEA: 104.21 (+0.88), AJX: 13.98 (+0.18), PLAY: 36.62 (+0.59), CTSH: 59.71 (+0.22), BLPH: 7.92 (-0.15), OMI: 33.76 (+0.58)
Eyegate Pharma closes IPO
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 11:42AM CST
Eyegate Pharma prices IPO
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:13AM CST
IPO Market Set For Another Surge In The Healthcare Sector
Renaissance Capital IPO Research - at Seeking Alpha - Mon Feb 02, 6:15PM CST
Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the two dividend-producing IPOs seek to price late in the week. The remaining eight...
AVGR: 12.90 (+0.18), IDGX: (), SLWD: (), ITEK: 5.11 (+0.25), REDX: (), INOV: 27.01 (+0.32), PUMP: (), CBYL: 7.26 (+0.31), NVET: 4.51 (-0.21), AAAP: ()
EyeGate Pharma back resets for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:29PM CST
Week Ahead: IPO Market Gains Momentum With 12 Deals Including Shake Shack And Health Care
Renaissance Capital IPO Research - Seeking Alpha - Tue Jan 27, 7:03AM CST
Twelve IPOs are set to raise $1 billion in the upcoming week, which would make it the busiest five-day stretch for IPOs since the week of July 28. Shake Shack's IPO offers investors a chance to own a fast-growing fast casual concept based in New...
AVGR: 12.90 (+0.18), SHAK: 50.50 (+0.07), ASND: 19.38 (-0.22), HIFR: 30.98 (unch), REDX: (), ONCE: 60.80 (+1.43), ENTL: 24.09 (-0.01), ZSAN: 8.26 (+0.49), FLKS: 17.02 (+0.52), LENS: 7.05 (+0.23), TCON: 10.80 (+0.13)
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mp6p4/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Alcon Nordic - Allergan - AlphaMab - Amakem - BIOCAD - Boehringer Ingelheim - Charlesson - Circadian Technologies - EyeCyte - EyeGate Pharmaceuticals - F. Hoffmann-La Roche - Genzyme - Icon Bioscience - Iconic Therapeutics - Intas Pharmaceuticals - Kala Pharmaceuticals - Lpath - Mesoblast - Neurotech Pharmaceuticals - Novartis - Ohr Pharmaceutical - Omeros Corporation - Ophthotech - Oxford BioMedica - PanOptica - Pfenex - Pfizer - Quark Pharmaceuticals - Regeneron Pharmaceuticals - Santen Pharmaceutical - Sanwa Kagaku Kenkyusho - Senju Pharmaceutical - TRACON Pharmaceuticals - Tacere Therapeutics - ThromboGenics - iCo Therapeutics - pSivida For more information visit http://www.researchandmarkets.com/research/9m...eovascular
AGN: 312.13 (+8.03), OHRP: 2.27 (-0.07), REGN: 526.01 (+16.98), OMER: 17.33 (+0.29), NVS: 103.22 (+3.20)
Cataract Therapeutic Pipeline Market Review by Companies and Drugs H2 2014 Report at RnRMarketResearch.com
PRWeb - Fri Nov 21, 7:31AM CST
The report "Cataract - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/cataract-pip...eport.html .
Solar Power, Biotechs Among 11 IPOs Planned This Week
at Investor's Business Daily - Mon Sep 29, 6:24PM CDT
The IPO market is maintaining a brisk pace with 11 scheduled this week, including a solar power company, three tech firms and three biotech companies. Vivint Solar (VSLR), a competitor to the Elon Musk-backed SolarCity (SCTY), plans to raise $350...
ATTO: 13.80 (-0.08), VWR: 25.43 (-0.23), JMEI: 19.32 (+0.58), ZEN: 21.44 (+0.35), VSLR: 11.34 (+0.39), JPEP: 12.97 (+0.11), W: 37.35 (+1.03), FMSA: 6.73 (-0.27), SCTY: 53.00 (+1.02), DERM: 18.22 (+0.30), AAC: 42.41 (-1.20), CALA: 6.77 (unch), AAVL: 16.25 (+0.62), YDLE: 14.67 (+0.56), JD: 32.40 (-0.38), BABA: 80.30 (+1.26)
